Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease

Rheumatology (United Kingdom)

Volumn 53, Issue 12, 2014, Pages 2196-2203

  Gono, Takahisa ^a   Kaneko, Hirotaka ^a   Kawaguchi, Yasushi ^a   Hanaoka, Masanori ^a   Kataoka, Sayuri ^a   Kuwana, Masataka ^b   Takagi, Kae ^a   Ichida, Hisae ^a   Katsumata, Yasuhiro ^a   Ota, Yuko ^a   Kawasumi, Hidenaga ^a   Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dermatomyositis; IL 6; IL 8; Interstitial lung disease; Polymyositis; TNF a

Indexed keywords

AMINOACYL TRANSFER RNA SYNTHETASE ANTIBODY; CYTOKINE; CYTOKINE ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; PREDNISOLONE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; DERMATOMYOSITIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSPNEA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; INTERSTITIAL LUNG DISEASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOSITIS INTENTION TO TREAT ACTIVITY INDEX SCORE; ODDS RATIO; PATHOPHYSIOLOGY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SERUM;

EID: 85027139673     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu258     Document Type: Article

References (33)

1. Callen J. Dermatomyositis. Lancet 2000;355:53–7.
2. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013;88:83–105.
3. Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012;71(Suppl 2):i82–5.
4. Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 2012;14:264–74.
5. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 2012;14:275–85.
6. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009;21:6 10–6.
7. Richards TJ, Eggebeen A, Gibson K et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009;60:2183–92.
8. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010;22:633–8.
9. Sato S, Hoshino K, Satoh T et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193–200.
10. Nakashima R, Imura Y, Kobayashi S et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 2010;49:433–40.
11. Gono T, Kawaguchi Y, Satoh T et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 2010;49:1713–9.
12. Sun WC, Sun YC, Lin H, Yan B, Shi GX. Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol 2012;167:1236–44.
13. Bohan A, Peter J. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7.
14. Sontheimer R. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002;46:626–36.
15. American Thoracic Society and European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277–304.
16. Bonaccorsi A, Cancellieri A, Chilosi M et al. Acute interstitial pneumonia: report of a series. Eur Respir J 2003;21: 187–91.
17. Miller FW, Rider LG, Chung YL et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262–73.
18. IMACS website. Disease activity core set measures. http://www.niehs.nih.gov/research/resources/collab/ imacs/diseaseactivity/index.cfm (4 June 2014, date last accessed).
19. Bilgic H, Ytterberg SR, Amin S et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60: 3436–46.
20. Reed AM, Peterson E, Bilgic H et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012;64:4078–86.
21. Miyazaki Y, Araki K, Vesin C et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995;96: 250–9.
22. Freeburn RW, Armstrong L, Millar AB. Cultured alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF) show dysregulation of lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) inductions. Eur Cytokine Netw 2005; 16:5–16.
23. Bargagli E, Prasse A, Olivieri C, Muller-Quernheim J, Rottoli P. Macrophage-derived biomarkers of idiopathic pulmonary fibrosis. Pulm Med 2011;2011:717130.
24. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958–69.
25. Pechkovsky DV, Prasse A, Kollert F et al. Alternatively activated alveolar macrophages in pulmonary fibrosismediator production and intracellular signal transduction. Clin Immunol 2010;137:89–101.
26. Benfield TL, Vestbo J, Junge J et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995;151: 1058–62.
27. Agrawal A, Zhuo H, Brady S et al. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. Am J Physiol Lung Cell Mol Physiol 2012;303:L634–9.
28. Groeneveld AB, Raijmakers PG, Hack CE, Thijs LG. Interleukin 8-related neutrophil elastase and the severity of the adult respiratory distress syndrome. Cytokine 1995;7: 746–52.
29. Ward P, Hunninghake G. Lung inflammation and fibrosis. Am J Respir Crit Care Med 1998;157(4 Pt 2):S123-9.
30. Greenberg SA, Pinkus JL, Pinkus GS et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664–78.
31. Walsh RJ, Kong SW, Yao Y et al. Type I interferoninducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784–92.
32. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008;20:17–22.
33. Tristano A. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit 2008;14:RA27–36.